Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

Publications 1.3k Datasets 392.5k Experiments 6

System / cell line: randomized ✕ Assay: drug ✕ Clear

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

PMID 9703286 · PMC2063030 · British journal of cancer · 1998 · 6 claims · 4 setups

Full-text index only

Paclitaxel/cisplatin therapy produces a higher positive response rate than cyclophosphamide/cisplatin therapy in advanced ovarian cancer

patients frozen genomic clinically randomized rt-pcr temporal
Getting it right: being smarter about clinical trials.

PMID 16608383 · PMC1435786 · PLoS medicine · 2006 · 9 claims · 8 setups

Full-text index only

Bias and confounding in observational studies can produce misleading associations that are overturned by randomized trials (e.g., HRT).

postmenopausal general patients men randomized population-based large
A mechanistic model captures the emergence and implications of non-genetic heterogeneity and reversible drug resistance in ER+ breast cancer cells.

PMID 34316714 · PMC8271219 · NAR cancer · 2021 · 7 claims · 8 setups

Has reproduction · 85

EMT and tamoxifen-resistance (TamR) regulatory axes can drive one another, enabling non-genetic heterogeneity via six co-existing phenotypes (ES, ER, HS, HR, MS, MR)

gene same randomized publicly racipe stochastic randomized
Human synthetic lethal inference as potential anti-cancer target gene detection.

PMID 20015360 · PMC2804737 · BMC systems biology · 2009 · 7 claims · 8 setups

Full-text index only

Targeting the synthetic lethal partner of a gene mutated in cancer selectively damages tumor cells while sparing healthy cells, offering a rationale for anti-cancer drug design

saccharomyces sapiens ihsln genes database phylogenetic gene
Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients.

PMID 18366776 · PMC2311324 · BMC neurology · 2008 · 6 claims · 3 setups

Full-text index only

ACE I/D genotype and allele distributions do not differ significantly between migraine patients and controls

genomic migraine pcr clinical
Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.

PMID 19014506 · PMC2615745 · Theoretical biology & medical modelling · 2008 · 8 claims · 6 setups

Full-text index only

A biphasic treatment approach—acute DA receptor blocking followed by long-term DA release/activation at the NAc—is needed to treat RDS without inducing abnormal mood or craving.

kidney alcohol-preferring obese rodents receptor dna-directed meta-analysis

Experiments

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

Getting it right: being smarter about clinical trials.

A mechanistic model captures the emergence and implications of non-genetic heterogeneity and reversible drug resistance in ER+ breast cancer cells.

Human synthetic lethal inference as potential anti-cancer target gene detection.

Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients.

Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.